Mondher Toumi,Bruno Falissard,Laurent Boyer et al.
Mondher Toumi et al.
Healthcare Professionals' Perceptions About Medical Cannabis in Greece: A Qualitative Study [0.03%]
希腊医疗专业人员对医用大麻的看法：一项定性研究
Christos Ntais,Yioula Melanthiou,Michael A Talias
Christos Ntais
Background: Medical cannabis continues to generate interest as a potential therapeutic option, yet its acceptance in clinical practice faces challenges, including regulatory barriers, social stigma, and gaps in scientific...
Strengthening the EU Health Technology Assessment Regulation: Integrating National Immunization Technical Advisory Groups for Comprehensive Vaccine Assessments [0.03%]
加强欧盟健康技术评估条例：整合国家免疫技术咨询小组以进行综合疫苗评估
Jasmijn Beekman,Adrianne de Roo,Sharon Wolters et al.
Jasmijn Beekman et al.
Background: Given their crucial role in vaccine assessment, National Immunization Technical Advisory Groups (NITAGs) should be considered in the Regulation on Health Technology Assessment (EU HTAR) to maximize the benefit...
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK [0.03%]
评估艾曲泊帕与 eltrombopag 和 romiplostim 治疗英国免疫性血小板减少症患者成本效益的比较研究
Nichola Cooper,Sebastian Guterres,Michał Pochopień et al.
Nichola Cooper et al.
Background: Thrombopoietin receptor agonists-romiplostim, eltrombopag and avatrombopag-are commonly used as second-line treatments for immune thrombocytopenia (ITP). ...
ARM's Perspective on the First Joint Clinical Assessments for ATMPs: Challenges and Opportunities on the Path Ahead [0.03%]
ARM对先进治疗产品联合临床评估首次应用的看法：前进道路上的挑战与机遇
Paolo Morgese,Stephen Majors,Dilip Patel
Paolo Morgese
Advanced Therapy Medicinal Products (ATMPs) are revolutionising modern medicine. By addressing the root cause rather than the symptoms of disease, ATMPs hold the promise of long-lasting benefits or even cures for severe, genetic, and rare d...
A Methodological Proposal for Health Technology Assessments: A Case Study on Biosimilar Drugs [0.03%]
健康技术评估的方法学建议——生物类似药案例研究
Marilisa Pia Dimmito,Lisa Marinelli,Eleonora Chiara Toto et al.
Marilisa Pia Dimmito et al.
This work proposes a methodological approach that could be useful in multidisciplinary health technology assessments (HTAs). Mathematical models based on real data were used to make predictions for the initial price and actual cost of three...
Clinical Trial Validity Guidance from the HTACG: Looking for Chicken Teeth [0.03%]
HTACG的临床试验有效性指南：寻找鸡的牙齿
Mondher Toumi,Bruno Falissard,Asma Jouini et al.
Mondher Toumi et al.
Ensuring the Efficiency and Effectiveness of Joint Clinical Assessment in National HTA Decision-Making: Insights from the 2024 CIRS Multi-Stakeholder Workshop [0.03%]
确保联合临床评估在国家卫生技术评估决策中的效率和效果：来自2024年CIRS多利益相关方研讨会的见解
Ting Wang,Neil McAuslane
Ting Wang
Background: This study explored the readiness and strategic considerations of companies and key stakeholders for the implementation of the Joint Clinical Assessment (JCA) under the European Health Technology Assessment Re...
The Integration of Social and Health Sectors in Scotland: An Analysis from the Prism of Different Public Policy Models [0.03%]
苏格兰社会部门和健康部门的融合：来自不同公共政策模型的分析
Ricardo Correia de Matos,Generosa do Nascimento,Adalberto Campos Fernandes et al.
Ricardo Correia de Matos et al.
The integration of health and social care has been a key focus in Scotland, driven by demographic changes, rising healthcare costs, and the need for more efficient service delivery. The Public Bodies (Joint Working) (Scotland) Act 2014 soug...
Public Health Decision-Maker Perspective on Joint Clinical Assessments in Central European EU Member States [0.03%]
中央欧洲欧盟成员国公共健康决策者对联合临床评估的看法
Gergő Merész,Dávid Dankó,Márk Péter Molnár
Gergő Merész
The HTA R introduces provisions that may benefit member states, in particular the opportunity to share national or regional assessment reports, cooperate outside of clinical domains, or use the methodological guidelines on a local level for...